Merck: global collaboration with Daiichi Sankyo
(CercleFinance.com) - Daiichi Sankyo and Merck announce a global collaboration for the development and commercialization of three Daiichi Sankyo DXd analog-to-digital converters.
This collaboration combines Daiichi Sankyo's expertise in ADCs and DXd technology with Merck's extensive experience in oncology and clinical development to advance and extend the reach of ADCs for patients with several types of cancer.
Daiichi Sankyo and Merck will jointly develop and commercialize patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan worldwide, apart from in Japan, where Daiichi Sankyo will retain exclusive rights.
Merck will pay Daiichi Sankyo an upfront payment of $4bn plus $1.5bn in payments over the next 24 months, and may make additional payments of up to $16.5bn, subject to the achievement of future sales milestones, for a total potential consideration of up to $22bn.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
This collaboration combines Daiichi Sankyo's expertise in ADCs and DXd technology with Merck's extensive experience in oncology and clinical development to advance and extend the reach of ADCs for patients with several types of cancer.
Daiichi Sankyo and Merck will jointly develop and commercialize patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan worldwide, apart from in Japan, where Daiichi Sankyo will retain exclusive rights.
Merck will pay Daiichi Sankyo an upfront payment of $4bn plus $1.5bn in payments over the next 24 months, and may make additional payments of up to $16.5bn, subject to the achievement of future sales milestones, for a total potential consideration of up to $22bn.
Copyright (c) 2023 CercleFinance.com. All rights reserved.